<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow CD34(+) cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (annexin V), proliferation (Ki-67), and Bcl-2-related protein expression was evaluated by flow cytometry in 102 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> secondary to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and in 30 <z:mpath ids='MPATH_458'>normal</z:mpath> donors (NBM) </plain></SENT>
<SENT sid="1" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was significantly increased in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA)/RA with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) (56.9% [20.4%-93.6%]) and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) (51.2% [25.2%-76 </plain></SENT>
<SENT sid="2" pm="."><plain>6%]) compared with NBM (16.7% [3.4%-35.3%], P &lt;.0001) </plain></SENT>
<SENT sid="3" pm="."><plain>In RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> always exceeded proliferation (Ki-67-positivity, 26.1% [9.5%-47.8%]; <z:mpath ids='MPATH_3'>apoptosis</z:mpath>:proliferation ratio 2.08 [1.15-3.63]); whereas in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, this ratio equalized (1.14 [0.93-2.08]) due to increased proliferation (40.4% [22%-69.5%]) </plain></SENT>
<SENT sid="4" pm="."><plain>Progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t)/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was associated with a significant reduction in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (22.3% [2.1%-53.2%]; P &lt;.0001) and proliferation (16.8% [1.9%-75.8%); P =.04; ratio 1.69 [0.16-12.21]) </plain></SENT>
<SENT sid="5" pm="."><plain>Pro-apoptotic (Bax/Bad) versus anti-apoptotic (Bcl-2/Bcl-X) Bcl-2-related protein ratios were increased in RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> compared with NBM (2.57 [1.93-9.42] versus 1.89 [0.65-4.1]; P =.06), whereas disease progression was associated with significantly reduced ratios (1.16 [0.06-3.32]; P &lt;.0001) due primarily to increased Bcl-2 expression </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> and Bax/Bad:Bcl-2/Bcl-X ratio were inversely correlated with both International Prognostic Scoring System score and cytogenetic risk group; highest levels observed in patients with low score and/or good risk cytogenetics </plain></SENT>
<SENT sid="7" pm="."><plain>There was a trend toward an association between Bcl-2-related protein expression and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (P =.07) </plain></SENT>
<SENT sid="8" pm="."><plain>This study indicates that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progression arises through multiple hits that alter levels of CD34(+) cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and proliferation </plain></SENT>
<SENT sid="9" pm="."><plain>Early disease is associated with excessive <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and elevated ratio of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> to proliferation </plain></SENT>
<SENT sid="10" pm="."><plain>Increased proliferative rates are observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, whereas leukemic transformation arises through inhibition of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> rather than excessive cell growth </plain></SENT>
<SENT sid="11" pm="."><plain>Although disease progression is accompanied by a fall in pro-apoptotic versus anti-apoptotic Bcl-2-related protein ratios, <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in patterns of protein expression indicates that factors additional to Bcl-2 family members play a role in the deregulated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>(Blood </plain></SENT>
<SENT sid="13" pm="."><plain>2000;96:3932-3938) </plain></SENT>
</text></document>